These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

201 related items for PubMed ID: 12615850

  • 21. In vitro activity of ketolides HMR 3004 and HMR 3647 and seven other antimicrobial agents against Corynebacterium diphtheriae.
    Engler KH, Warner M, George RC.
    J Antimicrob Chemother; 2001 Jan; 47(1):27-31. PubMed ID: 11152428
    [Abstract] [Full Text] [Related]

  • 22. Telithromycin: a brief review of a new ketolide antibiotic.
    Scheinfeld N.
    J Drugs Dermatol; 2004 Jan; 3(4):409-13. PubMed ID: 15303785
    [Abstract] [Full Text] [Related]

  • 23. Comparative in-vitro activity of ketolide HMR 3647 and four macrolides against gram-positive cocci of known erythromycin susceptibility status.
    Hamilton-Miller JM, Shah S.
    J Antimicrob Chemother; 1998 Jun; 41(6):649-53. PubMed ID: 9687104
    [Abstract] [Full Text] [Related]

  • 24. Evolving resistance patterns in community-acquired respiratory tract pathogens: first results from the PROTEKT global surveillance study. Prospective Resistant Organism Tracking and Epidemiology for the Ketolide Telithromycin.
    Felmingham D.
    J Infect; 2002 Feb; 44 Suppl A():3-10. PubMed ID: 12150493
    [Abstract] [Full Text] [Related]

  • 25. Overcoming antimicrobial resistance: profile of a new ketolide antibacterial, telithromycin.
    Leclercq R.
    J Antimicrob Chemother; 2001 Sep; 48 Suppl T1():9-23. PubMed ID: 11566972
    [Abstract] [Full Text] [Related]

  • 26. Pharmacodynamic and pharmacokinetic considerations in antimicrobial selection: focus on telithromycin.
    Drusano G.
    Clin Microbiol Infect; 2001 Sep; 7 Suppl 3():24-9. PubMed ID: 11523559
    [Abstract] [Full Text] [Related]

  • 27. Ketolides: a new class of antibacterial agents for treatment of community-acquired respiratory tract infections in a primary care setting.
    Clark JP, Langston E.
    Mayo Clin Proc; 2003 Sep; 78(9):1113-24. PubMed ID: 12962166
    [Abstract] [Full Text] [Related]

  • 28. Pharmacodynamics of telithromycin In vitro against respiratory tract pathogens.
    Odenholt I, Löwdin E, Cars O.
    Antimicrob Agents Chemother; 2001 Jan; 45(1):23-9. PubMed ID: 11120939
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. [Macrolides, ketolides and streptogramins].
    Mensa J, García-Vázquez E, Vila J.
    Enferm Infecc Microbiol Clin; 2003 Apr; 21(4):200-7; quiz 208, 219. PubMed ID: 12681133
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Comparative in vitro activity of telithromycin (HMR 3647), three macrolides, amoxycillin, cefdinir and levofloxacin against gram-positive clinical isolates in Japan.
    Okamoto H, Miyazaki S, Tateda K, Ishii Y, Yamaguchi K.
    J Antimicrob Chemother; 2000 Nov; 46(5):797-802. PubMed ID: 11062201
    [Abstract] [Full Text] [Related]

  • 34. Telithromycin.
    Spiers KM, Zervos MJ.
    Expert Rev Anti Infect Ther; 2004 Oct; 2(5):685-93. PubMed ID: 15482232
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Telithromycin.
    Balfour JA, Figgitt DP.
    Drugs; 2001 Oct; 61(6):815-29; discussion 830-1. PubMed ID: 11398913
    [Abstract] [Full Text] [Related]

  • 37. Activities of 16-membered ring macrolides and telithromycin against different genotypes of erythromycin-susceptible and erythromycin-resistant Streptococcus pyogenes and Streptococcus pneumoniae.
    Mazzariol A, Koncan R, Vitali LA, Cornaglia G.
    J Antimicrob Chemother; 2007 Jun; 59(6):1171-6. PubMed ID: 17405779
    [Abstract] [Full Text] [Related]

  • 38. Ketolides: pharmacological profile and rational positioning in the treatment of respiratory tract infections.
    Van Bambeke F, Harms JM, Van Laethem Y, Tulkens PM.
    Expert Opin Pharmacother; 2008 Feb; 9(2):267-83. PubMed ID: 18201149
    [Abstract] [Full Text] [Related]

  • 39. Postantibiotic suppression of growth of erythromycin A-susceptible and -resistant gram-positive bacteria by the ketolides telithromycin (HMR 3647) and HMR 3004.
    Munckhof WJ, Borlace G, Turnidge JD.
    Antimicrob Agents Chemother; 2000 Jun; 44(6):1749-53. PubMed ID: 10817748
    [Abstract] [Full Text] [Related]

  • 40. A new ketolide, HMR 3004, active against streptococci inducibly resistant to erythromycin.
    Rosato A, Vicarini H, Bonnefoy A, Chantot JF, Leclercq R.
    Antimicrob Agents Chemother; 1998 Jun; 42(6):1392-6. PubMed ID: 9624482
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.